Related Experiment Video
Updated: Feb 6, 2026
Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone
Published on: September 9, 2020
Sorafenib in patients with progressed and refractory bone tumors
Anna Raciborska1, Katarzyna Bilska2
1Department of Oncology and Surgical Oncology for Children and Youth, Institute of Mother and Child, 01-211 Warszawa, ul. Kasprzaka 17a, Warsaw, Poland. anna.raciborska@hoga.pl.
Abstract:
Patients with metastatic, progressive, or recurrent bone tumors have a dismal outcome. Sorafenib has been proposed as an effective salvage regimen for some malignancies. Thus, we sought to evaluate this approach for young patients with relapsed or refractory bone tumors. Twelve patients with refractory bone tumors (two with Ewing sarcoma, two with chondrosarcoma, and eight with osteosarcoma) received salvage treatment with sorafenib. All patients had standard tumor imaging and laboratory evaluation. All toxicities were documented. At the time of the beginning of sorafenib treatment median age among 12 patients was 18 years (range 4.1-27.9 years), eight were male, and eight had osteosarcoma. All received sorafenib because of relapse. Seven patients were treated parallel to other standard chemotherapy. Overall response rate was 75%. Median time to sorafenib time to progression for patients with osteosarcoma was 4 months (range 1.8-7.9 months). Four patients (33%) are alive, in that two with no evidence of disease with a median follow-up of 41 months (range 26.5-60.9 months). The estimated 5 year overall survival (OS) for the whole group was 64.49%. There were no serious toxicities. Sorafenib is well-tolerated in young patients with bone tumors, and particularly could be an option for patients with metastatic disease and refractory osteosarcoma. Sorafenib only allows to extend OS and different procedures are needed to achieve permanent remission. This regimen deserves further investigation in the upfront management of patients with high-risk bone tumors.
Insights
Sorafenib shows promise as a salvage treatment for young patients with refractory bone tumors, improving overall survival and demonstrating good tolerability. Further investigation is needed for upfront management of high-risk bone tumors.
Area of Science:
- Oncology
- Pediatric Oncology
- Pharmacology
Background:
- Metastatic, progressive, or recurrent bone tumors in young patients have a poor prognosis.
- Sorafenib is a targeted therapy with potential as a salvage regimen for refractory malignancies.
- Evaluating sorafenib in pediatric and young adult bone tumor patients is crucial.
Purpose of the Study:
- To assess the efficacy and tolerability of sorafenib as a salvage treatment for young patients with relapsed or refractory bone tumors.
- To determine the overall response rate, time to progression, and overall survival in this patient cohort.
- To identify potential toxicities associated with sorafenib in this population.
Main Methods:
- A cohort of 12 young patients with refractory bone tumors (Ewing sarcoma, chondrosarcoma, osteosarcoma) received salvage sorafenib treatment.
- Standard tumor imaging and laboratory evaluations were performed.
- Toxicities were meticulously documented throughout the treatment period.
Main Results:
- An overall response rate of 75% was observed.
- Median time to progression for osteosarcoma patients was 4 months.
- 33% of patients were alive at follow-up, with a 5-year overall survival of 64.49%.
- Sorafenib was well-tolerated with no serious toxicities reported.
Conclusions:
- Sorafenib is a well-tolerated salvage option for young patients with bone tumors, particularly those with metastatic or refractory osteosarcoma.
- Sorafenib can extend overall survival, but further strategies are required for durable remission.
- The study supports further investigation of sorafenib in the upfront management of high-risk bone tumors.
More Related Videos
Related Concept Videos
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
01:55Bone Structure
01:40Bone Remodeling
01:27Compact Bone
Compact bone, also called cortical bone, is the denser, stronger of the two types of bone tissue. It is found under the periosteum and in the diaphyses of long bones, where it provides support and protection. The microscopic structural unit of compact bone is called an osteon, or haversian system. Each osteon is composed of concentric rings of calcified...
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...